Population pharmacokinetic and pharmacodynamic modeling of evobrutinib in healthy adult participants

Evobrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, has shown therapeutic potential in relapsing multiple sclerosis. This analysis aimed to develop pharmacokinetic (PK) and pharmacodynamic (PD; BTK occupancy [BTKO]) models of evobrutinib and simulate PK and BTKO profiles under alternative...

Descripción completa

Detalles Bibliográficos
Autores principales: Papasouliotis, Orestis, Mitchell, David, Girard, Pascal, Dyroff, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747113/
https://www.ncbi.nlm.nih.gov/pubmed/36165192
http://dx.doi.org/10.1111/cts.13417

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747113/
https://www.ncbi.nlm.nih.gov/pubmed/36165192
http://dx.doi.org/10.1111/cts.13417

Ejemplares similares